Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) CFO James H. Mackaness sold 6,849 shares of the company’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $45.77, for a total value of $313,478.73. Following the completion of the sale, the chief financial officer now directly owns 148,914 shares in the company, valued at approximately $6,815,793.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Soleno Therapeutics Stock Performance
Shares of SLNO opened at $45.91 on Friday. Soleno Therapeutics, Inc. has a fifty-two week low of $3.69 and a fifty-two week high of $53.82. The company has a market capitalization of $1.53 billion, a PE ratio of -17.13 and a beta of -1.39. The stock has a fifty day moving average of $44.53 and a two-hundred day moving average of $44.41.
Soleno Therapeutics (NASDAQ:SLNO – Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.57) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.06. As a group, equities research analysts forecast that Soleno Therapeutics, Inc. will post -2.36 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Get Our Latest Stock Report on Soleno Therapeutics
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Victory Capital Management Inc. boosted its position in shares of Soleno Therapeutics by 26.3% in the second quarter. Victory Capital Management Inc. now owns 10,727 shares of the company’s stock worth $438,000 after acquiring an additional 2,236 shares during the last quarter. Aspiriant LLC acquired a new stake in shares of Soleno Therapeutics during the 4th quarter worth $488,000. Cannon Global Investment Management LLC purchased a new position in shares of Soleno Therapeutics in the 1st quarter worth $505,000. Sei Investments Co. boosted its holdings in Soleno Therapeutics by 22.0% in the first quarter. Sei Investments Co. now owns 12,577 shares of the company’s stock valued at $538,000 after acquiring an additional 2,264 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in Soleno Therapeutics during the second quarter valued at about $569,000. Institutional investors and hedge funds own 97.42% of the company’s stock.
Soleno Therapeutics Company Profile
Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.
Further Reading
- Five stocks we like better than Soleno Therapeutics
- How is Compound Interest Calculated?
- MarketBeat Week in Review – 8/5 – 8/9
- Buy P&G Now, Before It Sets A New All-Time High
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- What Are Trending Stocks? Trending Stocks Explained
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.